PRA Health Sciences (PRAH) received a Buy rating from Wolfe Research analyst Steve Baxter today. The company’s shares closed last Monday at $103.76.
According to TipRanks.com, Baxter is ranked #3932 out of 5664 analysts.
Currently, the analyst consensus on PRA Health Sciences is a Strong Buy with an average price target of $120.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $121.98 and a one-year low of $82.12. Currently, PRA Health Sciences has an average volume of 479.9K.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PRAH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PRA Health Sciences, Inc. engages in the provision of outsourced clinical development services to the biotechnology and pharmaceutical industries. It operates through Clinical Research and Data Solutios segment. The Clinical Research segment serves biopharmaceutical clients and offers outsourced clinical research and clinical trial related services.
